WAUSAU, Wis. (WSAW) – – The Aspirus Institute is recruiting participants for a clinical study that could improve future treatment options for people living with cardiovascular disease.

People who have had a heart attack or stroke, or who suffer from poor circulation may be candidates for this study.

This study examines the safety and potential benefits of the drugs kagrylintide and semaglutide (CagriSema) against cardiovascular events. During the study, researchers will track cardiovascular events (heart attacks, strokes, heart-related deaths), as well as changes in weight and A1C.

Participants may be eligible if:

• Have had a stroke, heart attack, or have poor circulation (peripheral artery disease)
• be over 55 years old
• Considered to be overweight or obese (BMI>25)
• have type 2 diabetes
• Possible chronic kidney disease
• Depending on the study start date, you will receive regular clinic visits and phone calls for 4 to 4.5 years.

Study sponsor Novo Nordisk expects the study to last up to four and a half years and enroll 7,000 participants in the U.S. and around the world.

“We are honored to have been selected to participate in this important clinical trial that translates the latest research findings into medical advances,” said interventional cardiologist German Larraín, M.D., principal investigator of the Aspirus study. Ta. “Research participants will know that they are helping others by contributing to this important research.”

All patients enrolled in the REDEFINE 3 study will be closely followed for up to 4.5 years. There are no costs associated with participation, and patients will be reimbursed for all study-related visits.

For more information about the REDEFINE 3 study, visit //aspirus.org/redefine3 or call Aspirus Research Institute at 715-847-2273.

Copyright 2024 WSAW. All rights reserved.